Xinyu (Annie) Li advises life sciences and technology companies in a broad range of corporate, operational, and transactional matters. She assists client in corporate formation, financing, licensing and strategic alliances, mergers and acquisitions, and general corporate governance matters. Her practice focuses on drafting and negotiating collaboration and license agreements, as well as research, development, supply, distribution, manufacturing, services, and other commercial agreements. She also has experience advising emerging companies and investors in their venture financing transactions.
Experience
- Transactions counsel to AcuraStem, a California biotech, in connection with its exclusive, worldwide license agreement with Takeda for its PIKFYVE program. If the agreed upon clinical, regulatory, and commercial milestones are met, AcuraStem will receive a total of US$580 million from Takeda in upfront and milestone payments. AcuraStem will also receive tiered royalties on any net sales.*
- Leading horizontal platform for cell programming, in its acquisition of adeno-associated virus (AAV) capsid discovery and engineering platform assets.*
- Biotechnology company in an agreement with a synthetic biology company developing new sustainable bio-based ingredients, in a multi-stage partnership focused on compounds in the tryptophan pathway.*
- Biotechnology company developing new ways to treat neurological disorders in its Series A financing.*
*Reflects experience at previous employer.
Credentials
Education
- J.D., Boston University School of Law, 2020
- B.A., Brandeis University, 2017, summa cum laude, Phi Beta Kappa
Admissions
- Massachusetts
Activities
- Member, Asian American Lawyers Association of Massachusetts
Languages
- Chinese (Mandarin)